Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Asset Writedowns and Impairment (2017 - 2025)

Perspective Therapeutics' Asset Writedowns and Impairment history spans 3 years, with the latest figure at $44000.0 for Q3 2024.

  • For Q3 2024, Asset Writedowns and Impairment changed N/A year-over-year to $44000.0; the TTM value through Sep 2024 reached $370000.0, up 9350.0%, while the annual FY2023 figure was $624000.0, N/A changed from the prior year.
  • Asset Writedowns and Impairment for Q3 2024 was $44000.0 at Perspective Therapeutics, down from $326000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $326000.0 in Q4 2023 and bottomed at $44000.0 in Q3 2024.